204873 | Complement C1, Human

204873
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      204873-200UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 200 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewNative, human C1 complement component. C1 is the first component of the classical complement pathway. It is a calcium-dependent complex of C1q, C1r, and C1s subcomponents which are present in the C1 complex at molar ratios of 1:2:2, respectively. Binding of C1 to classical pathway activators results in the conversion of the proenzyme C1s subcomponent to an active C1s enzyme. C1s enzyme cleaves both C4 and C2 resulting in formation of the C3 cleaving enzyme, C4b, C2a, of the classical complement pathway. C1 concentration is based on functional activity measurements relative to a normal serum standard pool.
          Catalogue Number204873
          Brand Family Calbiochem®
          References
          ReferencesCooper, N.R. 1985. Adv. Immunol. 37, 151.
          Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.
          Product Information
          FormLiquid
          FormulationIn 300 mM NaCl, 50 mM sodium acetate, 50 mM EACA, 25 µM NPGB, 10 mM benzamidine, 10 mM EDTA, 40% glycerol, pH 5.5.
          Applications
          Biological Information
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          204873

          References

          Reference overview
          Cooper, N.R. 1985. Adv. Immunol. 37, 151.
          Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision27-May-2008 RFH
          DescriptionNative, human C1 complement component. C1 is the first component of the classical complement pathway. It is a calcium dependent complex of C1q, C1r, and C1s subcomponents which are present in the C1 complex at molar ratios of 1:2:2 respectively. Binding of C1 to classical pathway activators results in the conversion of the proenzyme C1s subcomponent to an active C1s enzyme. C1s enzyme cleaves both C4 and C2, resulting in formation of the C3 cleaving enzyme, C4b, C2a, of the classical complement pathway. C1 concentration is based on functional activity measurements relative to a normal serum standard pool.
          FormLiquid
          FormulationIn 300 mM NaCl, 50 mM sodium acetate, 50 mM EACA, 25 µM NPGB, 10 mM benzamidine, 10 mM EDTA, 40% glycerol, pH 5.5.
          Concentration Label Please refer to vial label for lot-specific concentration
          SourcePrepared from plasma of individuals that have been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesCooper, N.R. 1985. Adv. Immunol. 37, 151.
          Ziccardi, R.J. and Cooper, N.R. 1977. J. Immunol. 118, 2047.